Dunn Edmund, Principal Accounting Officer at Monte Rosa Therapeutics ($GLUE), sold company shares on the open market five times over the past year, totaling about $492 thousand. His most recent sale occurred on March 4, 2026. These sales rank 6,487th among nearly 12,000 insiders in our database, where the average is $8.6 million across 6.4 transactions. Dunn Edmund made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 4, 2026 | Monte Rosa Therapeutics, Inc. | $GLUE | Dunn Edmund | Principal Accounting Officer | S | Common Stock | 139 | $17.96 | 22,554.0000 | 82,942,723 | 0.61% | 0.00% |
| March 2, 2026 | Monte Rosa Therapeutics, Inc. | $GLUE | Dunn Edmund | Principal Accounting Officer | M | Stock Option (Right to Buy) | 536 | $0.00 | 0.0000 | 82,942,723 | 100.00% | 0.00% |
| Feb. 27, 2026 | Monte Rosa Therapeutics, Inc. | $GLUE | Dunn Edmund | Principal Accounting Officer | M | Common Stock | 25164 | $13.41 | 47,857.0000 | 82,942,723 | 110.89% | 0.03% |
| March 2, 2026 | Monte Rosa Therapeutics, Inc. | $GLUE | Dunn Edmund | Principal Accounting Officer | S | Common Stock | 536 | $17.50 | 22,693.0000 | 82,942,723 | 2.31% | 0.00% |
| March 2, 2026 | Monte Rosa Therapeutics, Inc. | $GLUE | Dunn Edmund | Principal Accounting Officer | M | Common Stock | 536 | $13.41 | 23,229.0000 | 82,942,723 | 2.36% | 0.00% |
| Feb. 27, 2026 | Monte Rosa Therapeutics, Inc. | $GLUE | Dunn Edmund | Principal Accounting Officer | S | Common Stock | 25164 | $18.10 | 22,693.0000 | 82,942,723 | 52.58% | 0.03% |
| Feb. 27, 2026 | Monte Rosa Therapeutics, Inc. | $GLUE | Dunn Edmund | Principal Accounting Officer | M | Stock Option (Right to Buy) | 25164 | $0.00 | 536.0000 | 82,942,723 | 97.91% | 0.03% |
| Jan. 5, 2026 | Monte Rosa Therapeutics, Inc. | $GLUE | Dunn Edmund | Principal Accounting Officer | S | Common Stock | 1039 | $15.17 | 22,693.0000 | 82,942,723 | 4.38% | 0.00% |
| June 3, 2025 | Monte Rosa Therapeutics, Inc. | $GLUE | Dunn Edmund | Principal Accounting Officer | S | Common Stock | 2062 | $4.45 | 23,732.0000 | 73,910,026 | 7.99% | 0.00% |
| Jan. 2, 2025 | Monte Rosa Therapeutics, Inc. | $GLUE | Dunn Edmund | Principal Accounting Officer | A | Common Stock | 11850 | $0.00 | 25,794.0000 | 73,910,026 | 84.98% | 0.02% |
| Jan. 2, 2025 | Monte Rosa Therapeutics, Inc. | $GLUE | Dunn Edmund | Principal Accounting Officer | A | Stock Option (Right to Buy) | 53400 | $0.00 | 53,400.0000 | 73,910,026 | 9999.99% | 0.07% |
| July 5, 2024 | Monte Rosa Therapeutics, Inc. | $GLUE | Dunn Edmund | Principal Accounting Officer | S | Common Stock | 1610 | $3.83 | 13,944.0000 | 51,396,961 | 10.35% | 0.00% |
| June 3, 2024 | Monte Rosa Therapeutics, Inc. | $GLUE | Dunn Edmund | Principal Accounting Officer | S | Common Stock | 1207 | $4.04 | 15,554.0000 | 51,396,961 | 7.20% | 0.00% |
| Jan. 2, 2024 | Monte Rosa Therapeutics, Inc. | $GLUE | Dunn Edmund | Principal Accounting Officer | A | Stock Option (Right to Buy) | 25000 | $0.00 | 25,000.0000 | 51,396,961 | 9999.99% | 0.05% |
| Jan. 2, 2024 | Monte Rosa Therapeutics, Inc. | $GLUE | Dunn Edmund | Principal Accounting Officer | A | Stock Option (Right to Buy) | 35900 | $0.00 | 35,900.0000 | 51,396,961 | 9999.99% | 0.07% |